A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity
Primary Purpose
Weight
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
LIPO-102
LIPO-102 Low
LIPO-102, Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Weight focused on measuring Treatment of abdominal adiposity
Eligibility Criteria
Inclusion Criteria:
- 18 - 50 years old inclusive
- Localized area of abdominal subcutaneous adiposity of Grade 3 or above on the P-PNS or C-PNS
- BMI < 25kg/m sq
- Stable diet and exercise and body weight
Exclusion Criteria:
- Prior treatment of abdominal subcutaneous adipose tissue
- Females within 12 months postpardum
- Known hypersensitivity to the drugs or components
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
LIPO-102 High
LIPO-102, Low
LIPO-102; Placebo
Arm Description
Outcomes
Primary Outcome Measures
Safety
physical exam, ECG, vital signs, clinical assessment is injection site, clinical laboratory tests, and adverse events
Change in abdominal circumference
abdominal circumference
Secondary Outcome Measures
photographic assessment
abdominal circumference and volume reduction assessment
Abdominal subcutaneous adiposity questionnaire
Patient reported outcome
Patient and clinician photo numeric scale
patient and physician reports of change
Patient global assessment of severity scale
patient reports of change in severity
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01180465
Brief Title
A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity
Official Title
A Multi-center, Randomized, Double-masked, Placebo-controlled, Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
April 2010 (undefined)
Primary Completion Date
September 2010 (Actual)
Study Completion Date
September 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Neothetics, Inc
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
LIPO-102 is under evaluation for treatment of abdominal adiposity
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Weight
Keywords
Treatment of abdominal adiposity
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
160 (Actual)
8. Arms, Groups, and Interventions
Arm Title
LIPO-102 High
Arm Type
Experimental
Arm Title
LIPO-102, Low
Arm Type
Experimental
Arm Title
LIPO-102; Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
LIPO-102
Intervention Description
LIPO-102 High dose
Intervention Type
Drug
Intervention Name(s)
LIPO-102 Low
Intervention Description
LIPO-102 Low dose
Intervention Type
Drug
Intervention Name(s)
LIPO-102, Placebo
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Safety
Description
physical exam, ECG, vital signs, clinical assessment is injection site, clinical laboratory tests, and adverse events
Time Frame
8 weeks treatment and 1 week follow up
Title
Change in abdominal circumference
Description
abdominal circumference
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
photographic assessment
Description
abdominal circumference and volume reduction assessment
Time Frame
8 weeks
Title
Abdominal subcutaneous adiposity questionnaire
Description
Patient reported outcome
Time Frame
8 weeks
Title
Patient and clinician photo numeric scale
Description
patient and physician reports of change
Time Frame
8 weeks
Title
Patient global assessment of severity scale
Description
patient reports of change in severity
Time Frame
8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
18 - 50 years old inclusive
Localized area of abdominal subcutaneous adiposity of Grade 3 or above on the P-PNS or C-PNS
BMI < 25kg/m sq
Stable diet and exercise and body weight
Exclusion Criteria:
Prior treatment of abdominal subcutaneous adipose tissue
Females within 12 months postpardum
Known hypersensitivity to the drugs or components
Facility Information:
City
San Diego
State/Province
California
Country
United States
City
New York
State/Province
New York
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity
We'll reach out to this number within 24 hrs